Apyx Medical Corp

Apyx Medical Corp. operates as an energy-based medical technology company. The firm engages in developing, manufacturing, and marketing a range of electrosurgical products and technologies, as well as related medical products used the offices of doctors, surgery centers, and hospitals worldwide. It operates through the following segments: Advanced Energy and Original Equipment Manufacture (OME). The company was founded by Andrew Makrides in 1978 and is headquartered in Clearwater, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Apyx Medical Corp reports Q4 revenue decline, eyes 2023 growth

Apyx Medical Corp faced revenue challenges in Q4 2022, but secured new clearances and credit facilities.
The company anticipates improved revenue and profitability in 2023 with strategic initiatives.
Despite losses and reduced cash reserves, Apyx aims to enhance product offerings and financial stability.
Management's actions aim to address concerns and position the company for growth in 2023.

Apyx Medical Corp reports Q1 revenue beat but faces cost challenges

Apyx Medical Corp faced mixed results in Q1 2023 with revenue exceeding expectations but a decline in gross profit and net loss.
The company showcased strengths in OEM sales, product launches, and property transactions, while grappling with challenges in certain sales segments.
With revised revenue guidance, margin expectations, and growth opportunities, Apyx has a strategic roadmap for future performance improvements.

Apyx Medical Corp reports strong Q2 growth and reaffirms 2023 guidance

Apyx Medical Corp demonstrated robust growth in Q2 2023, driven by Advanced Energy product sales and operational efficiency improvements.
While facing challenges in certain regions and managing operating expenses, the company's strategic initiatives and revenue diversification are key strengths.
With reaffirmed financial guidance and opportunities for market expansion, Apyx is poised for continued growth and innovation in the medical device industry.

Apyx Medical Corp reports robust Q3 performance and strategic initiatives

Apyx Medical Corp's Q3 2023 earnings call showcased strong revenue growth, improved gross profit margins, and strategic initiatives to address challenges. With a focus on operational efficiency and new product introductions, the company aims to drive future growth and profitability.

Apyx Medical Corp reports strong Q4 revenue growth and eyes market expansion

Apyx Medical Corp delivered strong revenue growth in Q4 2023 driven by Advanced Energy products and international sales performance.
While facing challenges in net loss and operating expenses, the company's technology and clinical support remain key strengths.
Opportunities lie in financial growth targets, market recognition, and leveraging positive feedback to drive future success.
Overall, Apyx Medical Corp's performance reflects resilience and potential for growth in the medical technology sector.

Apyx Medical Corp reports Q1 revenue decline, focuses on cost control

Apyx Medical Corp faced revenue decline in Q1 2024, driven by lower Advanced Energy sales.
The company showcased strengths in cost control, operational achievements, and revenue diversification.
Challenges include declining Advanced Energy sales and a projected net loss for 2024.
Opportunities lie in driving Renuvion technology adoption and addressing segment sales challenges.

Apyx Medical Corp reports Q3 revenue decline, bets on Ayon

Apyx Medical Corp's Q3 2024 performance reflects a mixed financial picture with revenue decline but promising growth in key segments like disposable handpieces.
Management's strategic initiatives, including the Ayon system launch and cost-saving measures, aim to drive future growth and achieve cash flow breakeven by 2027.
While facing revenue challenges and financial losses, the company's focus on operational efficiency and product innovation presents opportunities for long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Apyx Medical Corporation (NASDAQ:APYX ) Q3 2024 Earnings Call Transcript November 8, 2024 8:00 AM ET Company Participants Jeremy Feffer - MD, LifeSci Advisors Stavros Vizirgianakis - Executive Chairman Charlie Goodwin - CEO Matt Hill - CFO Conference Call Participants Matthew O'Brien - Piper Sandler Matt Hewitt - Craig-Hallum Capital Group Sam Eiber - BTIG Ben Haynor - Lake Street Capital Markets Operator Ladies and gentlemen, good morning, and welcome to the Apyx Medical Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Apyx Medical Corporation (APYX) Q3 2024 Earnings Call Transcript

Apyx Medical (APYX) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.13 per share a year ago.

Apyx Medical (APYX) Reports Q3 Loss, Lags Revenue Estimates

CLEARWATER, Fla., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical” or the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced it has entered into a definitive purchase agreement with Nantahala Capital for the purchase and sale in a registered direct offering of 3,000,000 shares of the Company's common stock at a purchase price of $1.18 per share and pre-funded warrants to purchase up to 2,934,690 shares of the Company's common stock at a purchase price of $1.179 per pre-funded warrant (which represents the per share offering price for common stock less the exercise price per share for each pre-funded warrant of $0.001). The gross proceeds to Apyx Medical from the offering were approximately $7,000,000, before deducting offering expenses payable by the Company. The offering closed on November 8, 2024.

Apyx Medical Corporation Announces $7,000,000 Million Registered Direct Offering

CLEARWATER, Fla., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today reported the financial results for its third quarter ended September 30, 2024, updated its financial expectations for the full year ending December 31, 2024, and introduced its financial expectations for the full year ending December 31, 2025.

Apyx Medical Corporation Reports Third Quarter 2024 Financial Results; Updates Full Year 2024 Financial Outlook and Introduces Full Year 2025 Financial Outlook

CLEARWATER, Fla., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Apyx® Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced that financial results for the third quarter of fiscal year 2024 will be released before the market opens on Friday, November 8th.

Apyx Medical Corporation to Release Third Quarter Of Fiscal Year 2024 Financial Results on November 8, 2024

Apyx (APYX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Apyx (APYX) Upgraded to Buy: Here's What You Should Know

Independent survey reveals Renuvion is #1 trusted body contouring technology* with plastic and cosmetic surgeons. CLEARWATER, Fla.

Renuvion Named #1 Trusted Body Contouring Technology by Doctors*

Apyx Medical Corporation (NASDAQ:APYX ) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Charles Goodwin - President, Chief Executive Officer & Director Matthew Hill - Chief Financial Officer Conference Call Participants Matt Hewitt - Craig-Hallum Capital Frank Takkinen - Lake Street Capitals George Sellers - Stephens Inc Operator Hello, and welcome, ladies and gentlemen, to the Second Quarter of Fiscal Year 2024 Earnings Conference Call for Apyx Medical Corporation. At this time all participants have been placed in a listen-only more.

Apyx Medical Corporation (APYX) Q2 2024 Earnings Call Transcript

Apyx Medical (APYX) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.11 per share a year ago.

Apyx Medical (APYX) Reports Q2 Loss, Lags Revenue Estimates

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical”; the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced the publication of a peer-reviewed article in the journal, Plastic and Reconstructive Surgery—Global Open, featuring the results of study which compared the use of Renuvion's Helium Plasma Technology to InMode's Bipolar RF System (“Bipolar RF”) following li.

Apyx Medical Corporation Announces Peer-Reviewed Clinical Publication Comparing the Use of Renuvion to a Competing Technology Following Liposuction or Body Contouring Procedures

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today reported financial results for its second quarter ended June 30, 2024; and updated its financial expectations for the full year ending December 31, 2024. Second Quarter 2024 Financial Summary: Total revenue of $12.1 million, a decrease of 10% year-over-year. Advanced.

Apyx Medical Corporation Reports Second Quarter 2024 Financial Results; Updates Full Year 2024 Financial Outlook

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced that financial results for the second quarter of fiscal year 2024 will be released after the market closes on Thursday, August 8th. Management will host a conference call at 5:00 p.m. Eastern Time on August 8th to discuss the results of the quarter, and to host a question.

Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2024 Financial Results on August 8, 2024

Renuvion is the only device FDA-cleared for contracting subcutaneous tissue  CLEARWATER, Fla. , June 26, 2024 /PRNewswire/ -- Apyx® Medical Corporation (NASDAQ: APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the launch of the "Renewing Lives" campaign, a nationwide, life-changing give-back program that will provide Renuvion treatments to people who can most benefit from this advanced medical technology.

Apyx Medical Corporation Launches the "Renewing Lives" Give-Back Campaign Providing Treatments with Renuvion to Benefit Physical Appearance and Mental Health

Apyx Medical Corporation (NASDAQ:APYX ) Q1 2024 Results Conference Call May 9, 2024 8:00 AM ET Company Participants Charles Goodwin - President, Chief Executive Officer & Director Matt Hill - Chief Financial Officer Conference Call Participants Phillip Paul Dantoin - Piper Sandler Frank Takkinen - Lake Street Capitals Matt Hewitt - Craig-Hallum Capital George Sellers - Stephens Inc Operator Hello, and welcome, ladies and gentlemen, to the First Quarter of Fiscal Year 2024 Earnings Conference Call for Apyx Medical Corporation. [Operator Instructions].

Apyx Medical Corporation (APYX) Q1 2024 Earnings Call Transcript

Apyx Medical (APYX) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.10 per share a year ago.

Apyx Medical (APYX) Reports Q1 Loss, Tops Revenue Estimates

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported financial results for its first quarter ended March 31, 2024; and reaffirmed its financial expectations for the full year ending December 31, 2024. First Quarter 2024 Financial Summary: Total revenue of $10.2 million, a decrease of 16% year-over-year. Advanced Energy.

Apyx Medical Corporation Reports First Quarter 2024 Financial Results; Reaffirms Full Year 2024 Financial Outlook

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical”; the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the retirement of Andrew Makrides as Chairman of the Board, after serving the Company in this position since 1982. The Board of Directors has appointed Stavros Vizirgianakis Chairman of the Board, effective as of May 7, 2024. “On behalf of the entire organization, I.

Apyx Medical Corporation Announces Board Leadership Transition

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the first quarter of fiscal year 2024 will be released before the market opens on Thursday, May 9th. Management will host a conference call at 8:00 a.m. Eastern Time on May 9th to discuss the results of the quarter, and to host a question and answer sessi.

Apyx Medical Corporation to Release First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx® Medical Corporation (NASDAQ:APYX) (the “Apyx Medical”; “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, is pleased to announce the Renuvion Users' Summit is taking place in Las Vegas from April 12-13, 2024. The Renuvion Users' Summit brings together a diverse group of dedicated professionals in cosmetic and plastic surgery from 13 countries to share new research, applications, and c.

Apyx Medical Corporation Showcases New Data and Treatment Insights at the Renuvion® Users' Summit

Apyx Medical Corporation (APYX) Q4 2023 Earnings Call Transcript

Apyx Medical (APYX) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.17 per share a year ago.

Apyx Medical (APYX) Reports Q4 Loss, Tops Revenue Estimates

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported financial results for its fourth quarter and full year ended December 31, 2023, and introduced financial expectations for the full year ending December 31, 2024. Fourth Quarter 2023 Financial Summary: Total revenue of $14.7 million, an increase of 16% year-over-year.

Apyx Medical Corporation Reports Fourth Quarter and Full Year 2023 Financial Results; Introduces Full Year 2024 Financial Outlook

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx® Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the fourth quarter and fiscal year 2023 will be released before the market opens on Thursday, March 21st. Management will host a conference call at 8:00 a.m. Eastern Time on March 21st to discuss the results of the quarter and year, and to host a questio.

Apyx Medical Corporation to Release Fourth Quarter and Fiscal Year 2023 Financial Results on March 21, 2024

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (Nasdaq: APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that its Renuvion technology will be featured in three educational sessions at the upcoming American Academy of Cosmetic Surgery's 40th Annual Scientific Meeting, to be held in New Orleans, LA from February 22 – 24. “Apyx Medical is pleased to see Renuvion featured.

Apyx Medical Corporation Announces Renuvion to be Featured in Educational Sessions at the American Academy of Cosmetic Surgery (AACS) Scientific Meeting

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (Nasdaq: APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the publication of a peer-reviewed article in the Aesthetic Surgery Journal Open Forum, which evaluated the use of Renuvion for contracting subcutaneous soft tissue following liposuction in multiple areas of the body. “We are excited to see the publication of this.

Apyx Medical Corporation Announces Peer-Reviewed Clinical Publication Evaluating the Safety of Renuvion® Following Liposuction in Multiple Areas of the Body

News for Apyx Medical Corp Stock (APYX)